In another sign of biopharma's waning interest in the traditional ex vivo gene therapy approach, CSL Behring is shutti | CSL ...

Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...

In an update posted today, Neurogene said that the "emerging treatment-related serious adverse event (SAE)" was a case of ...

Based on a small trial with positive muscle performance data, Regenxbio is expected to pursue approval of its gene therapy ...

Researchers have developed a dual-gene therapy approach to treat Usher syndrome type 1F, a rare condition causing deafness and progressive blindness.

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.

Neurogene is proceeding with a scaled-back study of its proposed NGN-401 gene therapy for the rare genetic neurological disorder Rett syndrome after a serious adverse event left a study participant in ...

Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.

The 11th Cell Biology Industry Conference (CBIC) opened in Beijing, attracting more than 3,000 guests from clinical research ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

It is driven by developments in personalised medicine, gene therapy, and CRISPR technology. The global regenerative medicine ...